You are here: Industry Insights > Eylea

News List

Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis fiercepharma
April 18, 2019
Look out, Roche and Regeneron—Novartis eye candidate brolucizumab is on its way.
Post-Alcon Novartis eyes M&A in ophthalmic digital therapeutics fiercepharma
April 10, 2019
Now that Alcon is officially off on its own, what is Novartis’ remaining eye medicine business looking at next? According to Nikos Tripodis...
FDA to Review Eylea Injection americanpharmaceuticalreview
September 14, 2018
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of Eylea (aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading caus
Kodiak Sciences preps $100M IPO to advance AMD drug fiercebiotech
September 11, 2018
Kodiak's lead asset is designed to have a longer half-life than other anti-VEGF drugs. The hope is to improve patient adherence to a treatment that is injected into the eyes.
Days after FDA rejection, Regeneron wins label expansion for Eylea fiercepharma
August 20, 2018
Regeneron started the week with a piece of bad news that the FDA rejected Eylea in a new 12-week dosing formulation. But in an extremely quick reversal by the regulator, Regeneron on Friday secured the approval.
Regeneron plots DTC advertising and discount push to put Eylea back on track fiercepharma
August 03, 2018
Industry watchers already knew that Regeneron’s key new launches were hitting their marks, thanks to quarterly numbers Sanofi unveiled earlier this week. What they didn’t know was that top seller Eylea would fall short of expectations. But never fear, exe
Regeneron needs revved-up newcomers to backstop vulnerable Eylea—and so far, they're falling short fiercepharma
May 04, 2018
Regeneron's 15% growth in the first quarter came from its aging eye injection Eylea, while its newer drugs came short of expectations. That's not good—particularly with two potential new rivals threatening that blockbuster lead medication.
Physician Views: What opportunity for Eylea in diabetic retinopathy? firstwordpharma
April 26, 2018
With Regeneron Pharmaceuticals' Eylea having exited its imperious growth phase, the company is looking at opportunities to expand revenue for the franchise before competition intensifies.
Regeneron’s Eylea Shows Promising Data for Diabetic Retinopathy biospace
March 20, 2018
Regeneron Pharmaceuticals, Inc. announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
NICE nod for new Eylea indication pharmatimes
September 25, 2017
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.

Previous page 1 2 3 Next page